Evidence map›Paper›PMID 28862836›Full record

ArticleBioconjugate chemistry2017

Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain.

Ian Diner, Jeromy Dooyema, Marla Gearing, Lary C Walker, Nicholas T Seyfried

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Aβ Plaques.Free neuropathology · 2020
    Article
  6. Synthesis of Mono-ACS omega · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ian DinerDepartment of Biochemistry, ‡Yerkes National Primate Research Center, §Department of Pathology and Laboratory Medicine, and ∥Department of Neurology, Emory University , Atlanta, Georgia 30322, United States.
Jeromy DooyemaDepartment of Biochemistry, ‡Yerkes National Primate Research Center, §Department of Pathology and Laboratory Medicine, and ∥Department of Neurology, Emory University , Atlanta, Georgia 30322, United States.
Marla GearingDepartment of Biochemistry, ‡Yerkes National Primate Research Center, §Department of Pathology and Laboratory Medicine, and ∥Department of Neurology, Emory University , Atlanta, Georgia 30322, United States.
Lary C WalkerDepartment of Biochemistry, ‡Yerkes National Primate Research Center, §Department of Pathology and Laboratory Medicine, and ∥Department of Neurology, Emory University , Atlanta, Georgia 30322, United States.
Nicholas T SeyfriedDepartment of Biochemistry, ‡Yerkes National Primate Research Center, §Department of Pathology and Laboratory Medicine, and ∥Department of Neurology, Emory University , Atlanta, Georgia 30322, United States.ORCID 0000-0002-4507-624X
Emory University · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 1985 to 2011
$114.0M
The Emory Alzheimer's Disease CenterP50AG025688 · NIA · EMORY UNIVERSITY · PI WALKER, LARY C · 2005 to 2019
$25.7M
Discovery of Novel Proteomic Targets in Alzheimer's DiseaseU01AG046161 · NIA · EMORY UNIVERSITY · PI BENNETT, DAVID ALAN, GESCHWIND, DANIEL H · 2014 to 2018
$8.4M
ENNCF - Viral Vector CoreP30NS055077 · NINDS · EMORY UNIVERSITY · PI LEVEY, ALLAN I · 2008 to 2018
$6.8M
Tau-Spliceosome Interactions in Alzheimer's DiseaseR01AG053960 · NIA · BAYLOR COLLEGE OF MEDICINE · PI SEYFRIED, NICHOLAS THOMAS, SHULMAN, JOSHUA M · 2016 to 2020
$3.2M
NCRR NIH HHS P51 RR000165NIA NIH HHS P50 AG025688NIA NIH HHS R01 AG053960NIA NIH HHS U01 AG046161NIH HHS P51 OD011132NINDS NIH HHS P30 NS055077
6 · The paper itself

Abstract

The benzothiazole-aniline derivative Pittsburgh Compound B (PiB) is the prototypical amyloid affinity probe developed for the in vivo positron emission tomography (PET) detection of amyloid beta (Aβ) deposits in Alzheimer's disease (AD). Specific high-affinity binding sites for PiB have been found to vary among AD cases with comparable Aβ load, and they are virtually absent on human-sequence Aβ deposits in animal models, none of which develop the full phenotype of AD. PiB thus could be an informative probe for studying the pathobiology of Aβ, but little is known about the localization of PiB binding at the molecular or structural level. By functionalizing the 6-hydroxy position of PiB with a PEG

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsAnimalsBrainClick ChemistryHumansMagnetsMicrospheresPeptide FragmentsProtein AggregatesThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-Peptidesamyloid beta-protein (1-40)Aniline CompoundsPeptide FragmentsProtein AggregatesThiazoles

Identifiers

PMID28862836
PMCPMC5845826
OpenAlexW2750806729

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.